Peculiarities of Clinical Symptoms, Somatic Complications, Approaches to Therapy and Outcomes of Delirium Induced by Exposure to Synthetic Cannabinoids: Systematic Review

Abstract

INTRODUCTION: The use of synthetic cannabinoids (SCs) is an urgent healthcare problem, due to, among other things, a high number of complications.

AIM: To systematize the peculiarities of clinical presentation, somatic complications, effectiveness of empirical approaches to therapy, and probable outcomes of delirium induced by exposure to SCs.

MATERIALS AND METHODS: The analysis of scientific publications selected by the keywords in eLibrary, СNKI, PubMed databases, was conducted. According to PRISMA recommendations, 20 articles were taken for analysis.

RESULTS: Today, it is impossible to predict the period when SC-induced delirium may occur. It can start after one-time intake of even small dose, and can occur both due to intoxication and with the underlying withdrawal state — on the 2^nd–4^th days after the last use. Besides classic symptoms, the clinical picture of delirium is characterized by many symptoms of schizophrenic psychoses: hallucinations of threatening or drug-addicted content; secondary paranoid delusion, less expressed than hallucinations; aggressiveness and agitated behavior; some formal thinking disorders; rarely, Kandinski–Clerambault and oneiroid syndromes. There are reported cases of severe somatic complications in the form of depression of consciousness, rhabdomyolysis, acute renal failure, cardiomyopathy, myocardial infarction, epilepsy, infectious complications with the underlying weakened immunity. Therapy of SC-induced delirium includes detoxification and metabolic therapy, administration of antipsychotics and tranquilizers; use of resuscitation measures in case of depression of consciousness and development of life-threatening conditions. SC-induced delirium lasts from several hours to several days. In most cases, it terminates with complete recovery with amnesia of the period of confusion and asthenia, but in some cases fatal outcomes are reported caused not only by accidents such as road accidents or suicide, but also by somatic complications (most often of infectious character, or multi-organ failure).

CONCLUSION: SСs remain relevant due to high frequency of their use and continuous emergence of new analogs to substances of this group. They have multidirectional effect, and so far it is difficult to predict at what period the delirium induced by them may occur.

Keywords

synthetic cannabinoids / delirium / ICD-11

References

[1] UNODS. World drug report 2022. Vienna: Vienna intern. centre; 2022. Available at: https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2022.html. Accessed: 21.02.2023.

[2] Asadullin AR, Akhmetova EA, Yefremov IS, et al. New psychoactive substances (designer drugs): an approach to classification. Psychiatry and Psychopharmacotherapy. 2019;21(5):4–9. (In Russ).

[3] Асадуллин А.Р., Ахметова Э.А., Ефремов И.С., и др. Новые психоактивные вещества (дизайнерские наркотики): подход к классификации // Психиатрия и психофармакотерапия. 2019. Т. 21, № 5. С. 4–9.

[4] Klimenko TV, Shakhova SM, Kozlov AA. Psychotic disorders after use of synthetic cannabinoids (spice). Siberian Herald of Psychiatry and Addiction Psychiatry. 2017;(2):26–30. (In Russ).

[5] Клименко Т.В., Шахова С.М., Козлов А.А. Психотические расстройства вследствие употребления синтетических каннабиноидов (спайсов) // Сибирский вестник психиатрии и наркологии. 2017. Т. 50, № 2 (95). C. 26–30.

[6] Alves VL, Gonçalves JL, Aguiar J, et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359–82. doi: 10.1080/10408444.2020.1762539

[7] Alves V.L., Gonçalves J.L., Aguiar J., et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review // Crit. Rev. Toxicol. 2020. Vol. 50, No. 5. P. 359–382. doi: 10.1080/10408444.2020.1762539

[8] Armstrong F, McCurdy MT, Heavner MS. Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review. Pharmacotherapy. 2019;39(4):508–13. doi: 10.1002/phar.2241

[9] Armstrong F., McCurdy M.T., Heavner M.S. Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review // Pharmacotherapy. 2019. Vol. 39, No. 4. P. 508–513. doi: 10.1002/phar.2241

[10] Hobbs M, Kalk NJ, Morrison PD, et al. M. Spicing it up — synthetic cannabinoid receptor agonists and psychosis — a systematic review. Eur Neuropsychopharmacol. 2018;28(12):1289–304. doi: 10.1016/j.euroneuro.2018.10.004

[11] Hobbs M., Kalk N.J., Morrison P.D., et al. Spicing it up — synthetic cannabinoid receptor agonists and psychosis — a systematic review // Eur. Neuropsychopharmacol. 2018. Vol. 28, No. 12. P. 1289–1304. doi: 10.1016/j.euroneuro.2018.10.004

[12] ICD-11. Chapter 06. Mental and behavioral disorders and disorders of neuropsychic development. Statistical classification. Moscow; 2021. (In Russ). doi: 10.31453/kdu.ru.91304.0143

[13] МКБ-11. Глава 06. Психические и поведенческие расстройства и нарушения нейропсихического развития. Статистическая классификация. М.: «КДУ»; «Университетская книга»; 2021. doi: 10.31453/kdu.ru.91304.0143

[14] Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and refinement: updated guidance and examples for reporting systematic reviews. BMJ. 2021;372:n160. doi: 10.1136/bmj.n160

[15] Page M.J., Moher D., Bossuyt P.M., et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews // BMJ. 2021. Vol. 372. P. n160. doi: 10.1136/bmj.n160

[16] Bokhan NA, Selivanov GYu. Clinical typology of psychopathological disorders in users of synthetic cannabinoids (spice). Siberian Herald of Psychiatry and Addiction Psychiatry. 2015;(4):18–23. (In Russ).

[17] Бохан Н.А., Селиванов Г.Ю. Клиническая типология психо- патологических расстройств у потребителей синтетических канабин-ноидов (спайсов) // Сибирский вестник психиатрии и наркологии. 2015. № 4. С. 18–23.

[18] Berdnikova EA, Bayalieva AZh, Ustimov DYu, et al. Pathogenetically based sedative therapy of heavy delirium in overdose of synthetic cannabinoids. Vrach Skoroy Pomoshchi. 2017;(4):59–67. (In Russ).

[19] Бердникова Е.А., Баялиева А.Ж, Устимов Д.Ю. Патогенетически обоснованная седативная терапия тяжелого делирия при передозировке синтетических каннабиноидов // Врач скорой помощи. 2017. № 4. С. 59–67.

[20] Davydova VR, Ustimov DYu, Berdnikova EA. Patogeneticheski obosnovannaya efferentnaya i infuzionnaya terapiya tyazhelogo deliriya pri peredozirovke sinteticheskikh kannabinoidov. In: Aktual’nyye voprosy i innovatsionnyye tekhnologii v anesteziologii i reanimatologii: materialy nauchno-obrazovatel’noy konferentsii, Saint-Petersburg, 30–31 March 2018. Saint-Petersburg; 2018. P. 9–18. (In Russ).

[21] Давыдова В.Р., Устимов Д.Ю., Бердникова Е.А. Патогенетически обоснованная эфферентная и инфузионная терапия тяжелого делирия при передозировке синтетических каннабиноидов. В сб.: Актуальные вопросы и инновационные технологии в анестезиологии и реаниматологии: материалы научно-образовательной конференции, Санкт-Петербург, 30–31 марта 2018 г. СПб.; 2018. С. 9–18.

[22] Rakitin SA, Usov GM. Typology of psychotic disorders, associated with modern synthetic psychoactive substances. Psychiatry and Psychopharmacotherapy. 2020;22(6):31–6. (In Russ).

[23] Ракитин С.А., Усов Г.М. Типология психотических расстройств, развившихся на фоне употребления современных синтетических психоактивных веществ // Психиатрия и психофармакотерапия. 2020. Т. 22, № 6. С. 31–36.

[24] Ivanova LA, Terskikh TV, Tarasenko TV, et al. Psychotic disorders in people using synthetic cannabinoids (spices). Acta Biomedica Scientifica. 2017;2(2):14–7. (In Russ). doi: 10.12737/article_59a614f6883957.55938557

[25] Иванова Л.А., Терских Т.В., Тарасенко Т.В., и др. Психотические расстройства у лиц, употребляющих синтетические каннабиноиды (спайсы) // Acta Biomedica Scientifica. 2017. Т. 2, № 2. С. 14–17. doi: 10.12737/article_59a614f6883957.55938557

[26] Rakitin SA, Kukushkin MV, Mishchenko SV, et al. A clinical example of psychosis developed against the background of acute intoxication with synthetic cannabinoids. Omsk Journal of Psychiatry. 2020;(2):8–11. (In Russ). doi: 10.24411/2412-8805-2020-10206

[27] Ракитин С.А., Курушкин М.В., Мищенко С.В., и др. Клинический пример психоза, развившегося на фоне острой интоксикации синтетическими каннабиноидами // Омский психиатрический журнал. 2020. № 2 (25). С. 8–11. doi: 10.24411/2412-8805-2020-10206

[28] Vinnikova MA, Skryabin VYu. Psikhopatologicheskiye varianty psikhozov pri upotreblenii sinteticheskikh kannabinoidov. In: Interdistsiplinarnyy podkhod k komorbidnosti psikhicheskikh rasstroystv na puti k integrativnomu lecheniyu: sbornik tezisov, Saint-Petersburg, 15–18 May 2021. Saint-Petersburg: V. M. Bekhterev National Medical Research Center of Psychiatry and Neurology; 2021. P. 1099–100. (In Russ).

[29] Винникова М.А., Скрябин В.Ю. Психопатологические варианты психозов при употреблении синтетических каннабиноидов. В сб.: Интердисциплинарный подход к коморбидности психических расстройств на пути к интегративному лечению: сборник тезисов, Санкт-Петербург, 15–18 мая 2021 г. СПб.: Национальный медицинский исследовательский центр психиатрии и неврологии имени В. М. Бехтерева; 2021. С. 1099–1100.

[30] Vdovin AS. Clinical variants of psychoses associated with the use of synthetic cannabinoids. Narcology. 2022;(8):49–55. (In Russ). doi: 10.25557/1682-8313.2022.08.49-55

[31] Вдовин А.С. Клинические варианты психозов, связанных с употреблением синтетических каннабиноидов // Наркология. 2022. № 8. С. 49–55. doi: 10.25557/1682-8313.2022.08.49-55

[32] Patrikeeva ON, Ovchinnikov AA, Kormilina OM. Intoxication psychosis consumers synthetic cannabinoids. Narcology. 2015;(1):41–4. (In Russ).

[33] Патрикеева О.Н., Овчинников А.А., Кормилина О.М. Интоксикационные психозы у потребителей синтетических каннабиноидов // Наркология. 2015. № 1. С. 41–44.

[34] Kekelidze ZI, Klimenko TV, Kozlov AA, et al. Therapy of acute psychosis due to use of synthetic cannabinoids. Siberian Herald of Psychiatry and Addiction Psychiatry. 2017;(3):16–20. (In Russ). doi: 10.26617/1810-3111-2017-3(96)-16-20

[35] Кекелидзе З.И., Клименко Т.В., Козлов А.А., и др. Лечение острого психоза вследствие употребления синтетических каннабиноидов // Сибирский вестник психиатрии и наркологии. 2017. № 3 (96). С. 16–20. doi: 10.26617/1810-3111-2017-3(96)-16-20

[36] Gareeva AE, Sharafiev RR, Akhmetova EA, et al. The combined effect of genetic factors and attention deficit hyperactivity disorder on the development of dependence on synthetic cannabinoids. Zhurnal Nevrologii I Psikhiatrii imeni S.S. Korsakova. 2020;120(2):15–21. (In Russ). doi: 10.17116/jnevro202012002115

[37] Гареева А.Э., Шарафиев Р.Р., Ахметова Э.А., и др. Сочетанное влияние генетических факторов и синдрома дефицита внимания с гиперактивностью на развитие зависимости от синтетических каннабиноидов // Журнал неврологии и психиатрии им. C.C. Корсакова. 2020. Т. 120, № 2. С. 15–21. doi: 10.17116/jnevro202012002115

[38] Tyndall JA, Gerona R, de Portu G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol. 2015;53(10):950–6. doi: 10.3109/15563650.2015.1100306

[39] Tyndall J.A., Gerona R., de Portu G., et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA // Clin. Toxicol. 2015. Vol. 53, No. 10. P. 950–956. doi: 10.3109/15563650.2015.1100306

[40] Armenian P, Darracq M, Gevorkyan J, et al. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature. Neuropharmacology. 2018;134(Pt A):82–91. doi: 10.1016/j.neuropharm.2017.10.017

[41] Armenian P., Darracq M., Gevorkyan J., et al. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature Neuropharmacology. 2018. Vol. 134, Pt. A. P. 82–91. doi: 10.1016/j.neuropharm.2017.10.017

[42] Yazici AB, Yazici E, Erol A. Delirium and High Creatine Kinase and Myoglobin Levels Related to Synthetic Cannabinoid Withdrawal. Case Rep Med. 2017;2017:3894749. doi: 10.1155/2017/3894749

[43] Yazici A.B., Yazici E., Erol A. Delirium and high creatine kinase and myoglobin levels related to synthetic cannabinoid withdrawal // Case Rep. Med. 2017. Vol. 2017. P. 3894749. doi: 10.1155/2017/3894749

[44] Sweeney B, Talebi S, Toro D, et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med. 2016;34(1): 121.e1–2. doi: 10.1016/j.ajem.2015.05.052

[45] Sweeney B., Talebi S., Toro D., et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids // Am. J. Emerg. Med. 2016. Vol. 34, No. 1. P. 121.e1–121.e2. doi: 10.1016/j.ajem.2015.05.052

[46] Labay LM, Caruso JL, Gilson TP, et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int. 2016;260:31–9. doi: 10.1016/j.forsciint.2015.12.046

[47] Labay L.M., Caruso J.L., Gilson T.P., et al. Synthetic cannabinoid drug use as a cause or contributory cause of death // Forensic Sci. Int. 2016. Vol. 260. P. 31–39. doi: 10.1016/j.forsciint.2015.12.046

[48] Dmitrieva TB, Igonin AL, Klimenko TV, et al. Acute intoxication of psychoactive substances including opioides, cannabinoides, sedative and stimulative drugs, hallucinogens and solvents. Narcology. 2002;(7):8–12. (In Russ).

[49] Дмитриева Т.Б., Игонин А.Л., Клименко Т.В., и др. Острая интоксикация психоактивными веществами (опьянение опиоидами, каннабиноидами, седативно-снотворными средствами, стимуляторами, галлюциногенами и летучими растворителями) // Наркология. 2002. № 7. С. 8–12.

[50] Ergül DF, Ekemen S, Yelken BB. Synthetic Cannabinoid ‘Bonzai’ Intoxication: Six Case Series. Turk J Anaesthesiol Reanim. 2015;43(5): 347–51. doi: 10.5152/TJAR.2015.05668

[51] Ergül D.F., Ekemen S., Yelken B.B. Synthetic Cannabinoid ‘Bonzai’ Intoxication: Six Case Series // Turk. J. Anaesthesiol. Reanim. 2015. Vol. 43, No. 5. P. 347–351. doi: 10.5152/TJAR.2015.05668

[52] Schwartz MD, Trecki J, Edison LA, et al. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med. 2015;48(5):573–80. doi: 10.1016/j.jemermed.2014.12.038

[53] Schwartz M.D., Trecki J., Edison L.A., et al. A common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA // J. Emerg. Med. 2015. Vol. 48, No. 5. P. 573–580. doi: 10.1016/j.jemermed.2014.12.038

[54] Brandehoff N, Adams A, McDaniel K, et al. Synthetic cannabinoid “Black Mamba” infidelity in patients presenting for emergency stabilization in Colorado: a P-SCAN Cohort. Clin Toxicol (Phila). 2018;56(3):193–8. doi: 10.1080/15563650.2017.1357826

[55] Brandehoff N., Adams A., McDaniel K., et al. Synthetic cannabinoid “Black Mamba” infidelity in patients presenting for emergency stabilization in Colorado: a P-SCAN Cohort // Clin. Toxicol. (Phila.). 2018. Vol. 56, No. 3. P. 193–198. doi: 10.1080/15563650.2017.1357826

[56] Sinevich AA, Kopytov AV. Analiz produktivnoy simptomatiki po shkale pozitivnykh simptomov PANSS, u lits muzhskogo pola s zavisimost’yu ot kuritel’nykh smesey iz Respubliki Belarus’. Voyennaya Meditsina. 2016;(3):64–70. (In Russ).

[57] Синевич А.А., Копытов А.В. Анализ продуктивной симптоматики по шкале позитивных симптомов PANSS, у лиц мужского пола с зависимостью от курительных смесей из Республики Беларусь // Военная медицина. 2016. № 3. С. 64–70.

[58] Mendelevich VD. Psychotic disorders due to drug use: current state of the problem. Narcology. 2014;13(7):93–100. (In Russ).

[59] Менделевич В.Д. Психотические расстройства в результате употребления наркотиков: современное состояние проблемы // Наркология. 2014. Т. 13, № 7 (151). С. 93–100.

RIGHTS & PERMISSIONS

Eco-Vector